Russian Federation: Procedure For Veterinary Medicines Quality Control Sampling Comes Into Force

Last Updated: 14 August 2018
Article by Sergey Klimenko

The Federal Veterinary and Phytosanitation Service ("Rosselkhoznadzor") has issued Order No. 605 of June 13, 2018 (registered with the Ministry of Justice on July 20, 2018), entitled Approval of the Procedure for Veterinary Medicine Quality Control Sampling (the "Procedure"). The Procedure came into force on 3 August 2018. As of that date, Rosselkhoznadzor will exercise its powers under Art. 9 of Federal Law No. 61-FZ of April 12, 2010 On the Circulation of Pharmaceuticals to carry out quality control sampling of veterinary medicines ("VM") in accordance with the Procedure.

The objective of the sampling process is to ensure that VM and pharmaceutical substances meet the requirements set down by the official listing in the pharmacopeia or, if the substance is not listed, the requirements set down by statute or regulations.

The control process will enable the regulator to record the details of series and consignments of VM going into circulation in the RF. Officials will collect samples for laboratory testing, check that they meet statutory or regulatory requirements (the Procedure also sets out the grounds for and stages of the sampling process, the number of samples that should be taken and testing time frames) and make a decision as to whether the VM can go on to be distributed, whether they should be made subject to batch release testing (if more than one instance of non-compliance is found) and whether checks should be carried out at the entity that is putting the VM into circulation. All costs involved in batch release controls will be paid for by the producer or the holder or owner of the registration certificate.

If the expert report produced following sample testing does not clear the VM, Rosselkhoznadzor will issue a decision suspending the circulation of the VM batch on RF territory or, if a consignment of VM is found to be defective or fake, to withdraw it from circulation and destroy it (there is an official process for this). Notice of this will be published on Rosselkhoznadzor's website.

In addition, Rosselkhoznadzor will send the entity putting the VM into circulation (for VM registered in the RF) or the EEU controlling authority (for VM registered in another EEU member-state) an instruction for them to submit to Rosselkhoznadzor a program for averting threats to animal life and health. The program will have to be sent to Rosselkhoznadzor within 10 days.

The owner of defective or fake VM will be given 30 working days to comply with Rosselkhoznadzor's decision by withdrawing the VM from circulation and destroying them, although it will be possible to challenge decisions through the courts. In extreme cases, where urgent action is needed, Rosselkhoznadzor will have the power to order the owner of a consignment of VM to withdraw them from circulation within 2 days.

If other consignments of the batch of VM are in circulation and are found to meet statutory/regulatory requirements, Rosselkhoznadzor will issue a decision allowing them to remain in circulation and will publicly advise the entities distributing them of this.

The Procedure includes recommended forms for the sample request that Rosselkhoznadzor will send entities that distribute VM and the document recording the fact that samples have been taken and returned (called a sampling and dispatch act).

It is also important for VM producers to note that, under section 7 of the Procedure, entities that manufacture VM in Russia and/or import them to Russia will now have to give Rosselkhoznadzor the following details of batches and consignments of VM that are being put into circulation:

  • the (invented) name of the VM;
  • the INN;    
  • the form in which it is being released and number of units in a pack;
  • the manufacturer's name;
  • the amount of the batch/consignment being put into circulation on RF territory (for medicines – in terms of the number of packs; for pharmaceutical substances, in terms of units of measurement);
  • the registration certificate number or the number of the record of the pharmaceutical substance in the State Medicines Register;
  • the address of the site at which the consignment is being stored following confirmation by the manufacturer's authorized representative that the medicines meet the requirements set down during the state registration (release permit) process (for manufacturers in the RF);
  • the date that the manufacturer's authorized representative confirmed that the medicines meet the requirements set down during the state registration (release permit) process (for manufacturers in the RF);
  • the name of the entity putting the medicines into circulation on RF territory (for those importing to the RF);
  • the address of the site at which the consignment is being stored following clearance by the customs authorities through the customs regime it was declared under (for those importing to the RF); and
  • the date that the customs authorities cleared the consignment of medicines (for those importing to the RF).

This information has to be submitted within 5 business days from the time at which the manufacturer's authorized representative confirms that the batch of VM medicines meets the requirements set down during the state registration (release permit) process (for manufacturers in the RF) or from the date that it is imported to RF territory from an EEU country.

It is envisaged that these details will, at some future point, be entered in a Rosselkhoznadzor data management system 1 – now at the stage of development – then used to generate a VM quality control sampling plan. According to Rosselkhoznadzor (at http://fsvps.ru), during the transition period, details of batches and consignments of VM will need to be submitted by e-mail, to farmakonadzor@fsvps.ru.

The Procedure now sets down the main rules under which the authorized body will carry out quality control sampling for VM in circulation. The process has been made easier to understand and more predictable for entities involved in VM and there is a procedure for appealing against the regulator's decisions.

Dentons provides comprehensive legal services for Russian and foreign manufacturers of veterinary medicines and legal support during Rosselkhoznadzor inspections. It offers audits of product portfolios and develops recommendations to mitigate and eliminate risks identified.

Footnote

1. See Decree of the RF Government No. 1140 of November 7, 2016 On the Process of Creating, Developing and Operating the Federal State Veterinary Data Management System.

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
22 Jan 2019, Seminar, San Francisco, United States

Dentons is pleased to offer a full day of classes, just in time for the California MCLE compliance period deadline of January 31, 2019.*

23 Jan 2019, Seminar, Los Angeles, United States

Dentons is pleased to offer a full day of classes, just in time for the California MCLE compliance period deadline of January 31, 2019.*

24 Jan 2019, Other, New York, United States

Join Dentons’ Health Care Partner Lori Mihalich-Levin and White Collar & Government Investigations Counsel Christine Genaitis as they lead conference sessions at AHLA Academic Medical Centers and Teaching Hospitals Institute.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions